Olmesartan medoxomil/Amlodipine 40 mg/10 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

olmesartan medoxomil/amlodipine 40 mg/10 mg film-coated tablets

accord healthcare limited - amlodipine (as amlodipine besilate ph. eur.); olmesartan medoxomil - film-coated tablet - 40/10 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

AMLODIPINE/VALSARTAN NOVARTIS10/320 amlodipine 10 mg/valsartan 320 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan novartis10/320 amlodipine 10 mg/valsartan 320 mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; iron oxide yellow; titanium dioxide; hypromellose; purified talc; macrogol 4000 - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

AMLODIPINE/VALSARTAN NOVARTIS 5/320 amlodipine 5 mg/valsartan 320 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan novartis 5/320 amlodipine 5 mg/valsartan 320 mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: crospovidone; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; hypromellose; purified talc; iron oxide red; macrogol 4000 - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

AMLO 10 amlodipine 10 mg (as besilate) tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlo 10 amlodipine 10 mg (as besilate) tablet blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.867 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate - hypertension: amlo 10 tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoreceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlo 10 tablets are indicated for the first line treatment of chronic stable angina. amlo 10 tablets may be used alone, as monotherapy or in combination with other antianginal drugs.

AMLO 5 amlodipine 5 mg (as besilate) tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlo 5 amlodipine 5 mg (as besilate) tablet blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.9335 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate - hypertension: amlo 5 tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoreceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlo 5 tablets are indicated for the first line treatment of chronic stable angina. amlo 5 tablets may be used alone, as monotherapy or in combination with other antianginal drugs.

TERRY WHITE CHEMISTS AMLODIPINE amlodipine 2.5 mg (as besilate) tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

terry white chemists amlodipine amlodipine 2.5 mg (as besilate) tablet blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 3.5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; lactose monohydrate; magnesium stearate - hypertension - terry white chemists amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of terry white chemists amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina - terry white chemists amlodipine is indicated for the first line treatment of chronic stable angina. terry white chemists amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

AMLODIPINE Ireland - English - HPRA (Health Products Regulatory Authority)

amlodipine

wpr healthcare limited - amlodipine as amlodipine besilate - tablets - 5 milligram - amlodipine - calcium channel blockers, selective calcium channel blockers with mainly vascular effects - hypertension. chronic stable angina pectoris. vasospastic (prinzmetal’s) angina

AMLODIPINE Ireland - English - HPRA (Health Products Regulatory Authority)

amlodipine

wpr healthcare limited - amlodipine as amlodipine besilate - tablets - 10 milligram - amlodipine - calcium channel blockers, selective calcium channel blockers with mainly vascular effects - hypertension. chronic stable angina pectoris. vasospastic (prinzmetal’s) angina

AMLODIPINE/ATORVASTATIN-ZP 5/80 amlodipine (as besilate) 5mg / atorvastatin (as calcium) 80mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/atorvastatin-zp 5/80 amlodipine (as besilate) 5mg / atorvastatin (as calcium) 80mg film-coated tablet blister pack

medis pharma pty ltd - amlodipine besilate, quantity: 6.94 mg; atorvastatin calcium trihydrate, quantity: 86.8 mg - tablet, film coated - excipient ingredients: calcium carbonate; colloidal anhydrous silica; hyprolose; magnesium stearate; pregelatinised maize starch; croscarmellose sodium; microcrystalline cellulose; polysorbate 80; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - amlodipine/atorvastatin-zp (amlodipine and atorvastatin) is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented.,the indications for amlodipine are:,1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin converting enzyme inhibitor.,2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs,the indications for atorvastatin are:,1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

AMLODIPINE/ATORVASTATIN-ZP 5/40 amlodipine (as besilate) 5mg / atorvastatin (as calcium) 40mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/atorvastatin-zp 5/40 amlodipine (as besilate) 5mg / atorvastatin (as calcium) 40mg film-coated tablet blister pack

medis pharma pty ltd - amlodipine besilate, quantity: 6.94 mg; atorvastatin calcium trihydrate, quantity: 43.4 mg - tablet, film coated - excipient ingredients: calcium carbonate; colloidal anhydrous silica; hyprolose; magnesium stearate; pregelatinised maize starch; croscarmellose sodium; microcrystalline cellulose; polysorbate 80; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - amlodipine/atorvastatin-zp (amlodipine and atorvastatin) is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented.,the indications for amlodipine are:,1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin converting enzyme inhibitor.,2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs,the indications for atorvastatin are:,1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.